EA
EAPH.US Easton Pharmaceutica
- Market cap
- USD 26.9K
- P/E
- -
- P/B
- 0.00x
- ROE
- -5.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2021.
Is EAPH.US undervalued?
Graham numberThe Graham number of Easton Pharmaceutica cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Easton Pharmaceutica fundamental analysis
No fundamental analysis for Easton Pharmaceutica yet.
Easton Pharmaceutica stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Easton Pharmaceutica
Parallel Industries Inc. does not have significant operations. Previously, the company was involved in development and markets various topically delivered drugs to treat cancer and other therapeutic products to treat various conditions. It focuses on development, licenses, production, and markets prescription and over-the-counter products. The company was formerly known as Easton Pharmaceuticals Inc. and changed its name to Parallel Industries Inc. in December 2020. Parallel…
Full company profileEaston Pharmaceutica financial statements
2021 annualized: Fiscal year 2021 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2021, the balance sheet is the latest quarter. Figures change when the annual report is published.
Easton Pharmaceutica annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2010 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 67.4K | 0.00 | 44.0K | 153K | 379K | 1.56M | 0.00 | 0.00 |
| Gross Profit | - | 0.00 | 0.00 | 23.8K | 0.00 | 44.0K | 153K | 107K | 200K | 0.00 | - |
| Operating Income | - | -182K | -342K | -454K | -636K | -71.0K | 54.9K | -124K | -323K | -189K | -348K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -348K |
| Net Income | - | -183K | -347K | -361K | -600K | -873K | -245K | -169K | -323K | -189K | -348K |
| EPS | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 570K | 700K | 837K | 1.31M | 1.44M | 1.06M | 2.63M | 10.1M | 17.2M | 10.2M | 9.97M |
| Total Liabilities | 353K | 553K | 683K | 144K | 159K | 653K | 2.47M | 3.01M | 10.1M | 3.28M | 3.32M |
| Shareholders' Equity | 217K | 147K | 154K | 1.17M | 1.28M | 405K | 160K | 7.14M | 7.10M | 6.91M | 6.65M |
| Cash & Short-term Investments | 20.0K | 62.00 | 188K | 698K | 17.6K | 43.00 | 48.8M | 66.3K | 248K | 0.00 | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | -5.06K | -172K | -198K | -228K | -863K | -347K | -6.86K | 511K | -189K | -188K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 5.89M | 5.73M | 5.61M | 0.00 | 18.8K | 18.8K | 75.2K |
| Free Cash Flow | - | - | - | - | - | - | - | -6.86K | 511K | -189K | -188K |
| Ratios | |||||||||||
| ROE | - | -125.1% | -224.7% | -30.9% | -46.9% | -215.4% | -153.3% | -2.4% | -4.6% | -2.7% | -5.2% |
| ROA | - | -26.2% | -41.4% | -27.5% | -41.7% | -82.5% | -9.3% | -1.7% | -1.9% | -1.8% | -3.5% |
| Net Profit Margin | - | - | - | -535.2% | - | -1,983.7% | -160.3% | -44.7% | -20.8% | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Easton Pharmaceutica dividends
Easton Pharmaceutica has not paid dividends in the last 9 fiscal years.
Last stock split: 1:3000 on Apr 30, 2009.
Who owns Easton Pharmaceutica
Ownership data of Easton Pharmaceutica is not available yet.
Easton Pharmaceutica company profile
- Company name
- Easton Pharmaceutica
- Ticker
- EAPH.US
- Exchange
- USA Stocks
- Listed since
- Jul 22, 1999
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 111 Brockhouse Road, Toronto, ON, Canada
- Phone
- 647-362-5700
- Website
- eastonpharma.com
About Easton Pharmaceutica
Parallel Industries Inc. does not have significant operations. Previously, the company was involved in development and markets various topically delivered drugs to treat cancer and other therapeutic products to treat various conditions. It focuses on development, licenses, production, and markets prescription and over-the-counter products. The company was formerly known as Easton Pharmaceuticals Inc. and changed its name to Parallel Industries Inc. in December 2020. Parallel Industries Inc. was founded in 1997 and is headquartered in Toronto, Canada.
Easton Pharmaceutica management
4- Mr. Evan KarrasCEO, President, Secretary, Treasurer, CFO & Director · born 1971
- Dr. Lilla Albert Ph.D.Chief Marketing and Technology Officer
- Ms. Elena MilantoniDirector of Finance and Administration · born 1970
- Mr. Neil MellorSenior Business Consultant, Special Advisor and Member of Advisory Board